@freshman1：
cool！
freshman1
- Posts · 7Posts · 7
- Following · 0Following · 0
- Followers · 0Followers · 0
- Replying to @freshman1:isdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaefiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaeisdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouasozhsngiejsle//@freshman1:isdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfioj
- isdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaefiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouadjsiougjsdiogjioasdjgioasdhugsdughsaduhgusdagiojfiodgiuasdufgsdifmaiosdgiuasdbgiuasdniognsaodihgiuashgouansdignioaejfiouawenugnawiongiosdfgioasmiognaiowerngouaewngouewangouaewngowaeisdfiohsadhfgiosdaniogsahgaejifhasduhguasiofjadsijfiojsdioufhauehgiuasdgiouasozhsngiejsle//@freshman1:cool！cool！@freshman1：cool！
- congratulations！$TCOM 20250117 70.0 CALL$ $Trip.com Group Limited(TCOM)$ $TRIP.COM-S(09961)$ I could start thinking about applying for a Prime BTO.@Shernice軒嬣 2000：$TCOM 20250117 70.0 CALL$ $Trip.com Group Limited(TCOM)$ $TRIP.COM-S(09961)$ I could start thinking about applying for a Prime BTO.
- cool！Pre-market Focus | BeiGene bucks market trend, rising over 2%; tislelizumab officially launched in the US
Pre-market Focus | BeiGene bucks market trend, rising over 2%; tislelizumab officially launched in the US
本周三（10月9日），在中概股普遍大跌的背景下， $百济神州(BGNE)$ 美股盘前逆市涨超2%，截至发稿报240.9美元，涨幅2.32%。公司港股一度涨超8%，最终收涨3.8%。消息面上，百济神州的TEVIMBRA(替雷利珠单抗，中文商品名：百泽安)近日在美国正式商业化上市，用于治疗既往接受过系统化疗(不含PD-1/L1抑制剂)后不可切除或转移性食管鳞状细胞癌(ESCC)的成人患者。据悉，FDA目前还在对TEVIMBRA用于局部晚期不可切除或转移性ESCC患者的一线治疗，以及用于局部晚期不可切除或转移性胃或胃食管结合部(G/GEJ)腺癌患者的一线治疗进行审评。
